Case Reports - Andrology
Vol. 85 No. 1 (2013)
https://doi.org/10.4081/aiua.2013.1.36

Peyronie’s disease: A “triple oxygenant therapy”

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 19 April 2013
Published: 19 April 2013
3115
Views
3929
Downloads
Peyronie's disease, Pentoxifylline, Penile fibrosis, Phosphodiesterase inhibitors, Tadalafil, L-arginine

Authors

Francesco Ciociola
ciociolafrancesco@libero.it
U.O.C. Urologia 2 - Andrologia e Riproduzione Assistita, Azienda Ospedaliera San Paolo - Polo Universitario, Milano, Italy.
Giovanni Maria Colpi
U.O.C. Urologia 2 - Andrologia e Riproduzione Assistita, Azienda Ospedaliera San Paolo - Polo Universitario, Milano, Italy.
Objectives: To evaluate the effects of upregulators of nitric oxide in one patient with Peyronie’s disease, after non significant improvement following intracavernosal verapamil. Methods: A 20-years-old Caucasian male presented with penile induration in flaccid state, persistent during erection and associated with mild pain at third middle of penis. After treatment with intracavernosal verapamil for 4 months with relief of penile discomfort, followed by counseling on the use of penile extender for at least 6 hours per day, he was prescribed pentoxifylline associated with tadalafil plus levo-arginine, propionil-carnitine and Vitamin B3. Results: After almost 2 years, the septal thickness was reduced at ultrasound evaluation after this “triple oxygenant therapy”. Conclusion: NO-iNOS biology in Peyronie patients is the very protagonist in modulating penile fibrosis through up-regulation of NO-cGMP pathway that influences penile health by preventing and reversing fibrosis in the tunical albuginea.

Downloads

Download data is not yet available.

How to Cite



Peyronie’s disease: A “triple oxygenant therapy”. (2013). Archivio Italiano Di Urologia E Andrologia, 85(1), 36-40. https://doi.org/10.4081/aiua.2013.1.36

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.